Overview

* Inogen Q2 2025 revenue rises 4% yr/yr, beating analyst expectations, per LSEG data

* Adjusted net loss for Q2 improves to $0.7 mln, beating analyst estimates, per LSEG data

* Co raises full-year 2025 revenue guidance, expects adjusted EBITDA breakeven

Outlook

* Inogen raises full-year 2025 revenue guidance to $354 mln-$357 mln

* Company expects full-year 2025 Adjusted EBITDA breakeven

* Inogen projects Q3 2025 revenue of $91 mln-$93 mln

* Company sees 4% year-over-year growth in Q3 2025 revenue

Result Drivers

* BUSINESS-TO-BUSINESS GROWTH - Revenue growth driven by increased demand from international and domestic business-to-business customers

* PRODUCT INTRODUCTIONS - Launch of Voxi 5 and Inogen Patient Portal aimed at expanding product offerings and improving patient engagement

* REVENUE OFFSET - Growth partially offset by declines in direct-to-consumer and rental revenue

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $92.30 $90.60

Revenue mln mln (3

Analysts

)

Q2 Beat -$700,00 -$6.77

Adjusted 0 mln (3

Net Analysts

Income )

Q2 Net -$4.20

Income mln

Q2 Beat $2.10 $100,000

Adjusted mln (3

EBITDA Analysts

)

Q2 Gross 44.8%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

* Wall Street's median 12-month price target for Inogen Inc ( INGN ) is $13.00, about 51.5% above its August 6 closing price of $6.30

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)